3i made a strategic decision to back the EMBL Technology Fund as a way to invest in early-stage venture capital deals . Based in Heidelberg, the team have proprietary deal flow emanating from the European Molecular Biology Labs (EMBL) as well as a strong network enabling them to invest in early stage deals in Europe. 3i has co-invested with the fund in Immatics, a leader in cancer vaccines.